Boston Scientific (NYSE:BSX) Stock Sale Revealed by Rep. Kevin Hern

29 Sep 2026, 18:05 by Tristan Rich · The Markets Daily

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $50,001 and $100,000 in Boston Scientific stock on September 4th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Boston Scientific Price Performance

BSX traded down $0.64 during midday trading on Tuesday, hitting $43.47. 5,451,113 shares of the company traded hands, compared to its average volume of 18,739,535. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $105.65. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The business has a 50 day simple moving average of $46.97 and a two-hundred day simple moving average of $52.24. The company has a market capitalization of $63.00 billion, a price-to-earnings ratio of 17.60, a PEG ratio of 1.05 and a beta of 0.57.

Boston Scientific (NYSE:BSX – Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Stifel Nicolaus set a $60.00 price target on Boston Scientific in a research report on Wednesday, July 29th. Wells Fargo & Company reduced their price objective on Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating on the stock in a research report on Wednesday, September 23rd. Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Finally, Mizuho dropped their price target on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Twenty-three equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $70.19.

Read Our Latest Stock Analysis on BSX

Insiders Place Their Bets

In other Boston Scientific news, Director Edward Ludwig acquired 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Michael Mahoney bought 186,240 shares of Boston Scientific stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have bought 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by corporate insiders.

Institutional Trading of Boston Scientific

A number of large investors have recently made changes to their positions in the company. Kelleher Financial Advisors purchased a new stake in shares of Boston Scientific during the second quarter worth approximately $25,000. Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific in the first quarter valued at $28,000. Rakuten Securities Inc. purchased a new position in Boston Scientific in the second quarter valued at about $30,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Boston Scientific during the 1st quarter valued at approximately $32,000. Finally, Cetera Trust Company N.A purchased a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $32,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Boston Scientific Company Profile

(Get Free Report)

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.